Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALIGN TECHNOLOGY INCALGN · Entity 3488 | Director | August 27, 2026 | August 31, 2026 |
| Alphatec Holdings, Inc.ATEC · Entity 4720 | Director | June 10, 2026 | June 12, 2026 |
| DEXCOM INCDXCM · Entity 3114 | Chief Operating Officer | September 08, 2021 | September 10, 2021 |
| NUVASIVE INCNUVA · Entity 110002 | CFO | February 08, 2017 | February 10, 2017 |
| iRhythm Holdings, Inc.IRTC · Entity 1499 | Director · President and CEO | August 07, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALIGN TECHNOLOGY INC
Report date August 27, 2026 · Filed August 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,376 |
Reported balance
After 2026-08-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-27 · Grant · Acquired 1,376 · Balance 1,376 F1: 100% of the RSUs granted on August 27, 2026 will become vested on the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the RSUs granted on August 27, 2026 will become vested on the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date.
Alphatec Holdings, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 600,381 |
Reported balance
After 2026-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 32,012 · Balance 600,381 F1: On June 10, 2026, issuer granted to the reporting person 32,012 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the earlier of (a) the next annual meeting of stockholders and (b) the death or resignation of the reporting person. In the event of death or resignation of the reporting person, the grant will vest pro-rata based on the number of actual days served by the reporting person from the time of the grant to such death or resignation, divided by 365. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2026, issuer granted to the reporting person 32,012 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the earlier of (a) the next annual meeting of stockholders and (b) the death or resignation of the reporting person. In the event of death or resignation of the reporting person, the grant will vest pro-rata based on the number of actual days served by the reporting person from the time of the grant to such death or resignation, divided by 365.
DEXCOM INC
Report date September 08, 2021 · Filed September 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,280 |
Last balance in matching sequence
After 2021-09-10 transaction · row 14
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
14 source rowsRow 1 · 2021-09-08 · Sale · Disposed 7,639 · Balance 30,303 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 2 · 2021-09-08 · Sale · Disposed 42 · Balance 30,261 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 3 · 2021-09-09 · Sale · Disposed 1,534 · Balance 28,727 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 4 · 2021-09-09 · Sale · Disposed 19 · Balance 28,708 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 5 · 2021-09-09 · Sale · Disposed 515 · Balance 28,193 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4: This transaction was executed in multiple trades at prices ranging from $541.36 to $541.79. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 6 · 2021-09-09 · Sale · Disposed 300 · Balance 27,893 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5: This transaction was executed in multiple trades at prices ranging from $542.55 to $543.40. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 7 · 2021-09-09 · Sale · Disposed 100 · Balance 27,793 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 8 · 2021-09-09 · Sale · Disposed 100 · Balance 27,693 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 9 · 2021-09-09 · Sale · Disposed 900 · Balance 26,793 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6: This transaction was executed in multiple trades at prices ranging from $546.75 to $547.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 10 · 2021-09-09 · Sale · Disposed 1,200 · Balance 25,593 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7: This transaction was executed in multiple trades at prices ranging from $547.885 to $548.790. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 11 · 2021-09-09 · Sale · Disposed 2,394 · Balance 23,199 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8: This transaction was executed in multiple trades at prices ranging from $548.93 to $549.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 12 · 2021-09-09 · Sale · Disposed 2,200 · Balance 20,999 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9: This transaction was executed in multiple trades at prices ranging from $549.95 to $550.84. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 13 · 2021-09-09 · Sale · Disposed 200 · Balance 20,799 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10: This transaction was executed in multiple trades at prices ranging from $551.15 to $551.42. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 14 · 2021-09-10 · Sale · Disposed 1,519 · Balance 19,280 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022.
F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F4: This transaction was executed in multiple trades at prices ranging from $541.36 to $541.79. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F5: This transaction was executed in multiple trades at prices ranging from $542.55 to $543.40. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F6: This transaction was executed in multiple trades at prices ranging from $546.75 to $547.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F7: This transaction was executed in multiple trades at prices ranging from $547.885 to $548.790. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F8: This transaction was executed in multiple trades at prices ranging from $548.93 to $549.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F9: This transaction was executed in multiple trades at prices ranging from $549.95 to $550.84. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F10: This transaction was executed in multiple trades at prices ranging from $551.15 to $551.42. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
NUVASIVE INC
Report date February 08, 2017 · Filed February 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| PRSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 13,203 |
Reported balance
After 2017-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-08 · Grant · Acquired 13,203 · Balance 13,203 F1: Each performance restricted stock unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: This PRSU award was granted to the Reporting Person on March 1, 2016. On February 8, 2017, the Compensation Committee of the Issuer's Board of Directors certified that the PRSU award's performance condition had been satisfied. In accordance with the terms of the PRSU award, the award will vest in full on March 1, 2019. As the PRSU award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance restricted stock unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2: This PRSU award was granted to the Reporting Person on March 1, 2016. On February 8, 2017, the Compensation Committee of the Issuer's Board of Directors certified that the PRSU award's performance condition had been satisfied. In accordance with the terms of the PRSU award, the award will vest in full on March 1, 2019. As the PRSU award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant.
iRhythm Holdings, Inc.
Report date August 07, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 226,008 |
Ending reported balance
After 2026-08-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-07 · Grant · Acquired 48,534 · Balance 252,867 F1: Represents the acquisition of shares upon the determination of the Compensation & Human Capital Management Committee of the Board of Directors of the Issuer that the performance conditions were met with respect to performance Restricted Stock Units ("RSUs") granted to the Reporting Person on August 7, 2023. Row 2 · 2026-08-10 · Sale · Disposed 26,859 · Balance 226,008 F2: These shares were sold to cover tax withholding and remittance obligations in connection with the vesting of performance RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the acquisition of shares upon the determination of the Compensation & Human Capital Management Committee of the Board of Directors of the Issuer that the performance conditions were met with respect to performance Restricted Stock Units ("RSUs") granted to the Reporting Person on August 7, 2023.
F2: These shares were sold to cover tax withholding and remittance obligations in connection with the vesting of performance RSUs.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Axogen, Inc.
Report date March 30, 2022 · Filed April 01, 2022
Section 16 reporting ended · disclosed 2022-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,335 |
Reported balance
After 2022-03-30 transaction · row 1
1 source rowRow 1 · 2022-03-30 · Exercise / conversion · Acquired 3,036 · Balance 27,335 F1: This reflects the number of restricted stock units that became vested as of March 30, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-03-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-30 · Exercise / conversion · Disposed 3,036 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. This grant was accelerated by Axogen's Board of Directors to vest upon departure. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of restricted stock units that became vested as of March 30, 2022.
F2: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F3: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. This grant was accelerated by Axogen's Board of Directors to vest upon departure.
Paragon 28, Inc.
Report date April 21, 2025 · Filed April 21, 2025
Section 16 reporting ended · disclosed 2025-04-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 1
1 source rowRow 1 · 2025-04-21 · Disposition to issuer · Disposed 50,554 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the "Merger Agreement"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. ("Parent"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $13.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $1.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent, Equiniti Trust Company, LLC, as rights agent, and, for certain provisions, Zimmer Biomet Holdings, Inc., as guarantor. F3: At the Effective Time, each outstanding restricted stock unit solely subject to time-based vesting conditions vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award, (x) the Cash Consideration and (y) one CVR. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the "Merger Agreement"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. ("Parent"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $13.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $1.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent, Equiniti Trust Company, LLC, as rights agent, and, for certain provisions, Zimmer Biomet Holdings, Inc., as guarantor.
F3: At the Effective Time, each outstanding restricted stock unit solely subject to time-based vesting conditions vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award, (x) the Cash Consideration and (y) one CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2021 Filed Sep 10, 2021 20:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $551.28 | $110,255.00 |
DisclosureSEC source: 0001093557-21-000202 · edgardoc.xml · nonDerivative · entry 13 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,799 F3 · shares: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $551.15 to $551.42. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,200 | $550.51 | $1,211,130.80 |
DisclosureSEC source: 0001093557-21-000202 · edgardoc.xml · nonDerivative · entry 12 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,999 F3 · shares: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $549.95 to $550.84. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,394 | $549.45 | $1,315,371.33 |
DisclosureSEC source: 0001093557-21-000202 · edgardoc.xml · nonDerivative · entry 11 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,199 F3 · shares: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $548.93 to $549.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,200 | $548.40 | $658,075.20 |
DisclosureSEC source: 0001093557-21-000202 · edgardoc.xml · nonDerivative · entry 10 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,593 F3 · shares: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $547.885 to $548.790. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 900 | $547.28 | $492,549.30 |
DisclosureSEC source: 0001093557-21-000202 · edgardoc.xml · nonDerivative · entry 9 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,793 F3 · shares: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $546.75 to $547.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $545.10 | $54,510.00 |
DisclosureSEC source: 0001093557-21-000202 · edgardoc.xml · nonDerivative · entry 8 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,693 F3 · shares: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $543.66 | $54,366.00 |
DisclosureSEC source: 0001093557-21-000202 · edgardoc.xml · nonDerivative · entry 7 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,793 F3 · shares: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 300 | $542.83 | $162,849.90 |
DisclosureSEC source: 0001093557-21-000202 · edgardoc.xml · nonDerivative · entry 6 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,893 F3 · shares: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $542.55 to $543.40. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 515 | $541.45 | $278,846.24 |
DisclosureSEC source: 0001093557-21-000202 · edgardoc.xml · nonDerivative · entry 5 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,193 F3 · shares: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $541.36 to $541.79. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 19 | $542.03 | $10,298.53 |
DisclosureSEC source: 0001093557-21-000202 · edgardoc.xml · nonDerivative · entry 4 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,708 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,534 | $541.36 | $830,446.24 |
DisclosureSEC source: 0001093557-21-000202 · edgardoc.xml · nonDerivative · entry 3 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,727 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 20:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 42 | $546.31 | $22,944.85 |
DisclosureSEC source: 0001093557-21-000202 · edgardoc.xml · nonDerivative · entry 2 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,261 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 20:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,639 | $545.87 | $4,169,900.93 |
DisclosureSEC source: 0001093557-21-000202 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,303 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 18:15 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | GrantCommon Stock | 10,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006868 · edgar.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,151 F1 · security: On June 16, 2021, issuer granted to the reporting person 10,221 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the earlier of (a) the next annual meeting of stockholders and (b) the death or resignation of the reporting person. In the event of death or resignation of the reporting person, the grant will vest pro-rated based on the number of actual days served by the reporting person from the time of the grant to such death or resignation, divided by 365. F1 · shares: On June 16, 2021, issuer granted to the reporting person 10,221 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the earlier of (a) the next annual meeting of stockholders and (b) the death or resignation of the reporting person. In the event of death or resignation of the reporting person, the grant will vest pro-rated based on the number of actual days served by the reporting person from the time of the grant to such death or resignation, divided by 365. F1 · price: On June 16, 2021, issuer granted to the reporting person 10,221 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the earlier of (a) the next annual meeting of stockholders and (b) the death or resignation of the reporting person. In the event of death or resignation of the reporting person, the grant will vest pro-rated based on the number of actual days served by the reporting person from the time of the grant to such death or resignation, divided by 365. F1 · balance_after: On June 16, 2021, issuer granted to the reporting person 10,221 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the earlier of (a) the next annual meeting of stockholders and (b) the death or resignation of the reporting person. In the event of death or resignation of the reporting person, the grant will vest pro-rated based on the number of actual days served by the reporting person from the time of the grant to such death or resignation, divided by 365. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:13 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 3,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000109 · wf-form4_162275477699109.xml · derivative · entry 4 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,036 Underlying: Common Stock · 3,036 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:13 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 6,030 | $0.00 Strike: $19.76 | $0.00 |
DisclosureSEC source: 0000805928-21-000109 · wf-form4_162275477699109.xml · derivative · entry 3 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires 2031-06-01 F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:13 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000109 · wf-form4_162275477699109.xml · derivative · entry 2 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: This reflects the number of restricted stock units that became vested as of June 1, 2021. F2 · derivative.expiration_date: This reflects the number of restricted stock units that became vested as of June 1, 2021. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:13 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000109 · wf-form4_162275477699109.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 01:14 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,223 | $375.00 | $2,708,625.00 |
DisclosureSEC source: 0001093557-21-000161 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,942 F1 · shares: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 37,709 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 6,144 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:38 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,509 | $362.22 | $2,357,688.03 |
DisclosureSEC source: 0001093557-21-000073 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,165 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 37,709 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 6,144 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:25 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 7,491 | $0.00 | $7.49 |
DisclosureSEC source: 0001093557-21-000051 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,674 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 37,709 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 6,144 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| November 03, 2020 Filed Jan 26, 2021 19:08 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | GiftCommon Stock | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000830 · edgar.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 513,930 Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 171 | $405.33 | $69,311.43 |
DisclosureSEC source: 0001093557-20-000249 · edgardoc.xml · nonDerivative · entry 11 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,124 F3 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 43,950 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 272 | $403.87 | $109,853.86 |
DisclosureSEC source: 0001093557-20-000249 · edgardoc.xml · nonDerivative · entry 10 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,295 F3 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $403.28 to $404.25. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 43,950 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,159 | $402.72 | $869,471.40 |
DisclosureSEC source: 0001093557-20-000249 · edgardoc.xml · nonDerivative · entry 9 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,567 F3 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $402.23 to $403.08. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 43,950 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,157 | $401.79 | $1,268,454.50 |
DisclosureSEC source: 0001093557-20-000249 · edgardoc.xml · nonDerivative · entry 8 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,726 F3 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $401.21 to $402.20. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 43,950 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,017 | $399.91 | $1,206,535.71 |
DisclosureSEC source: 0001093557-20-000249 · edgardoc.xml · nonDerivative · entry 7 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,883 F3 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $399.55 to $400.345. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 43,950 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,594 | $398.98 | $635,978.42 |
DisclosureSEC source: 0001093557-20-000249 · edgardoc.xml · nonDerivative · entry 6 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,900 F3 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $398.55 to $399.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 43,950 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,300 | $397.76 | $517,090.34 |
DisclosureSEC source: 0001093557-20-000249 · edgardoc.xml · nonDerivative · entry 5 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,494 F3 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $397.47 to $398.384. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 43,950 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 523 | $397.03 | $207,647.27 |
DisclosureSEC source: 0001093557-20-000249 · edgardoc.xml · nonDerivative · entry 4 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,794 F3 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $396.29 to $397.22. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 43,950 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,579 | $398.30 | $628,918.86 |
DisclosureSEC source: 0001093557-20-000249 · edgardoc.xml · nonDerivative · entry 3 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,317 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 43,950 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,297 | $398.30 | $1,313,201.69 |
DisclosureSEC source: 0001093557-20-000249 · edgardoc.xml · nonDerivative · entry 2 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,896 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 43,950 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 8,010 | $398.30 | $3,190,399.02 |
DisclosureSEC source: 0001093557-20-000249 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,193 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 43,950 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,216 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 21:36 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,591 | $11.75 | $30,444.25 |
DisclosureSEC source: 0001179110-20-009632 · edgar.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,126 F1 · shares: This reflects the number of restricted stock units that became vested as of September 3, 2020. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 21:53 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | GrantCommon Stock | 28,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007663 · edgar.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,180 F1 · security: On June 17, 2020, issuer granted to the reporting person 28,013 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the 12 month anniversary of the grant date. F1 · shares: On June 17, 2020, issuer granted to the reporting person 28,013 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the 12 month anniversary of the grant date. F1 · price: On June 17, 2020, issuer granted to the reporting person 28,013 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the 12 month anniversary of the grant date. F1 · balance_after: On June 17, 2020, issuer granted to the reporting person 28,013 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the 12 month anniversary of the grant date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:49 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 4,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006903 · edgar.xml · derivative · entry 2 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,115 Underlying: Common Stock · 4,115 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:49 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 16,807 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-006903 · edgar.xml · derivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,807 Underlying: Common Stock · 16,807 shares Expires 2030-06-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:21 UTC Amendment | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007281 · edgar.xml · derivative · entry 2 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,173 Underlying: Common Stock · 6,173 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F3 · balance_after: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:21 UTC Amendment | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 12,605 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-007281 · edgar.xml · derivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,605 Underlying: Common Stock · 12,605 shares Expires 2030-06-01 F3 · shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F3 · balance_after: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $244.78 | $24,478.00 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 18 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,203 F4 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 400 | $244.01 | $97,604.00 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 17 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,303 F4 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F15 · price: This transaction was executed in multiple trades at prices ranging from $243.55 to $244.27. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $241.06 | $120,532.00 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 16 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,703 F4 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F14 · price: This transaction was executed in multiple trades at prices ranging from $240.77 to $241.42. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,100 | $239.63 | $263,595.97 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 15 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,203 F4 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F13 · price: This transaction was executed in multiple trades at prices ranging from $239.02 to $239.97. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 600 | $238.29 | $142,972.02 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 14 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,303 F4 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F12 · price: This transaction was executed in multiple trades at prices ranging from $237.85 to $238.53. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 641 | $237.10 | $151,979.56 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 13 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,903 F4 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $236.74 to $237.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 472 | $235.90 | $111,343.86 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 12 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,544 F4 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $235.69 to $236.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 300 | $234.23 | $70,269.99 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 11 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,016 F4 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $233.98 to $234.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $232.00 | $46,400.00 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 10 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,316 F4 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $228.86 | $45,772.00 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 9 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,516 F4 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 400 | $227.56 | $91,025.00 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 8 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,716 F4 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $227.18 to $228.11. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.